Evidence map›Paper›PMID 33176797›Full record

ArticleJournal of neuroinflammation2020

Complement peptide C3a receptor 1 promotes optic nerve degeneration in DBA/2J mice.

Jeffrey M Harder, Pete A Williams, Catherine E Braine, Hongtian S Yang, Jocelyn M Thomas, Nicole E Foxworth, Simon W M John, Gareth R Howell

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 45 citations in OpenAlex.

  1. Neuroinflammation in glaucoma: a myriad of cellular pathways and players.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Dual role of complement in neuronal repair.Frontiers in immunology · 2025
    Review
  12. Article
  13. Article
  14. The Role of Complement Dysregulation in Glaucoma.International journal of molecular sciences · 2024
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Jeffrey M HarderThe Jackson Laboratory, Bar Harbor, ME, USA.
Pete A WilliamsThe Jackson Laboratory, Bar Harbor, ME, USA.ORCID http://orcid.org/0000-0001-6194-8397
Catherine E BraineThe Jackson Laboratory, Bar Harbor, ME, USA.
Hongtian S YangThe Jackson Laboratory, Bar Harbor, ME, USA.
Jocelyn M ThomasThe Jackson Laboratory, Bar Harbor, ME, USA.
Nicole E FoxworthThe Jackson Laboratory, Bar Harbor, ME, USA.
Simon W M JohnThe Jackson Laboratory, Bar Harbor, ME, USA. sj2967@cumc.columbia.edu.
Gareth R HowellThe Jackson Laboratory, Bar Harbor, ME, USA. gareth.howell@jax.org.ORCID http://orcid.org/0000-0003-0565-6474
Jackson Laboratory · USTufts University · USKarolinska Institutet · SE

Funding

Instrumentation, Fabrication, and Design CoreP30EY019007 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Xin Zhang · 2010 to 2026
$12.9M
Factors Determining Intraocular Pressure and Glaucoma SusceptibilityR01EY011721 · NEI · JACKSON LABORATORY · PI JOHN, SIMON W · 2002 to 2018
$12.4M
Investigating Cell Specific Roles of the Complement Cascade in GlaucomaR01EY021525 · NEI · JACKSON LABORATORY · PI HOWELL, GARETH R · 2012 to 2016
$2.5M
FACTORS DETERMINING INTRAOCULAR PRESSURER29EY011721 · NEI · JACKSON LABORATORY · PI JOHN, SIMON W · 1997 to 2001
$227k
NEI NIH HHS EY011721NEI NIH HHS EY021525NEI NIH HHS P30 EY019007NEI NIH HHS R01 EY011721NEI NIH HHS R01 EY021525NEI NIH HHS R29 EY011721
6 · The paper itself

Abstract

backgroundThe risk of glaucoma increases significantly with age and exposure to elevated intraocular pressure, two factors linked with neuroinflammation. The complement cascade is a complex immune process with many bioactive end-products, including mediators of inflammation. Complement cascade activation has been shown in glaucoma patients and models of glaucoma. However, the function of complement-mediated inflammation in glaucoma is largely untested. Here, the complement peptide C3a receptor 1 was genetically disrupted in DBA/2J mice, an ocular hypertensive model of glaucoma, to test its contribution to neurodegeneration.

methodsA null allele of C3ar1 was backcrossed into DBA/2J mice. Development of iris disease, ocular hypertension, optic nerve degeneration, retinal ganglion cell activity, loss of RGCs, and myeloid cell infiltration in C3ar1-deficient and sufficient DBA/2J mice were compared across multiple ages. RNA sequencing was performed on microglia from primary culture to determine global effects of C3ar1 on microglia gene expression.

resultsDeficiency in C3ar1 lowered the risk of degeneration in ocular hypertensive mice without affecting intraocular pressure elevation at 10.5 months of age. Differences were found in the percentage of mice affected, but not in individual characteristics of disease progression. The protective effect of C3ar1 deficiency was then overcome by additional aging and ocular hypertensive injury. Microglia and other myeloid-derived cells were the primary cells identified that express C3ar1. In the absence of C3ar1, microglial expression of genes associated with neuroinflammation and other immune functions were differentially expressed compared to WT. A network analysis of these data suggested that the IL10 signaling pathway is a major interaction partner of C3AR1 signaling in microglia.

conclusionsC3AR1 was identified as a damaging neuroinflammatory factor. These data help suggest complement activation causes glaucomatous neurodegeneration through multiple mechanisms, including inflammation. Microglia and infiltrating myeloid cells expressed high levels of C3ar1 and are the primary candidates to mediate its effects. C3AR1 appeared to be a major regulator of microglia reactivity and neuroinflammatory function due to its interaction with IL10 signaling and other immune related pathways. Targeting myeloid-derived cells and C3AR1 signaling with therapies is expected to add to or improve neuroprotective therapeutic strategies.

Indexed as

AnimalsAnimals, NewbornCells, CulturedFemaleGene Regulatory NetworksMaleMiceMice, Inbred DBAMice, KnockoutMice, TransgenicNerve DegenerationOptic NerveReceptors, Complementcomplement C3a receptorReceptors, ComplementAnaphylatoxinComplementGlaucomaMicrogliaMonocytesNeurodegeneration

Identifiers

PMID33176797
PMCPMC7656757
OpenAlexW3102161185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.